HEAD & NECK CANCERS

Results from a phase II trial demonstrated that cemiplimab, a PD-1 inhibitor, induced an overall response rate (ORR) of 47.5% in patients with metastatic cutaneous squamous cell carcinoma.

According to study results presented at the 2018 ASCO Annual Meeting, women with head and neck cancer (HNC) are less likely to recieve intensive chemotherapy and radiation when compared with their male counterparts.

In results of a large randomized trial of patients with head and neck cancer who had undergone radiation therapy, patients who used mobile and sensor technology to track their symptoms demonstrated reduced severity of their symptoms compared with patients who received standard care.

Patients with metastatic or recurrent squamous cell carcinoma of the head and neck experienced a 32% reduction in the risk of death compared with investigator's choice of therapy, according to updated findings with a minimum of 2 years of follow-up from the phase III CheckMate-141 study.

Lung Cancer

The FDA has placed a clinical hold on a phase I/II study of axalimogene filolisbac and durvalumab, according to an announcement by Advaxis, the manufacturer of axalimogene filolisbac, in a quarterly earnings report.The study is evaluating the combination in patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck squamous cell carcinoma.